MFIM
KERX

Mesirow Financial Investment Management’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Mesirow Financial Investment Management’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-40,014
Closed -$284K – 63
2017
Q3 		$284K Buy
+40,014
New +$288K 1.34% 47

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Mesirow Financial Investment Management's KERX Position: Q4 2017 in Review

Mesirow Financial Investment Management sold out of Keryx Biopharmaceuticals Inc (KERX) in Q4 2017, closing a stake of 40,014 shares — an estimated $284K sold.

Mesirow Financial Investment Management first reported a position in KERX in Q3 2017 and held it in 1 quarter. The position peaked at $284K in Q3 2017. 129 funds tracked by Wall St. Rank hold KERX as of Q4 2017.

  • Mesirow Financial Investment Management reported no remaining Keryx Biopharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
  • Mesirow Financial Investment Management sold 40,014 Keryx Biopharmaceuticals Inc shares in Q4 2017, an estimated $284K.
  • Mesirow Financial Investment Management first reported a position in Keryx Biopharmaceuticals Inc in Q3 2017 and held it in 1 quarter.
  • Mesirow Financial Investment Management's Keryx Biopharmaceuticals Inc position peaked at $284K in Q3 2017.
  • 129 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q4 2017.

Based on Mesirow Financial Investment Management's 13F filing for Q4 2017, filed 16 Jan 2018.